EUCTR2006-002852-13-DE进行中（未招募）不适用
Double blind, placebo-controlled dose escalating, multiple dose study with two groups of 30 volunteers with type II diabetes to assess efficacy on glucose-profile, triglycerides and blood pressure and pharmacokinetics of two different doses of BLX-1002
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female subjects with type II diabetes and increased triglyceride level of any ethic origin who are non- or light smokers (= 10 cig./day), 30 through 75 years of age, will be recruited from the local population and 60 eligible subjects will be included in the study after having given voluntary written informed consent before first invasive screening examination procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •·Type I diabetes
- •·Treatment with insulin
- •·History of ketoacidosis or unstable diabetes with severe hypoglycemic episodes
- •·History of cardiac problems:
- •- decompensated heart failure (NYHA III to IV).
- •- diagnosis of angina pectoris.
- •- previous myocardial infarction
- •- ischemic heart disease, confirmed by ECG
- •·History of cancer or presence of cancer, or any clinically significant respiratory, renal, hepatic, gastrointestinal, venereal, hematological, or psychiatric diseases or disorder.
- •·Severe diabetic peripheral neuropathy, severe diabetic retinopathy or symptomatic diabetic nephropathy requiring tight glycaemic control.
- •·Major surgery within the last year, major illness within one month before the screening examination or any febrile illness within one week prior to screening and up to the first medication.
- •·Severe digestive disorder or surgery of the digestive tract (except for appendectomy)
- •·Participation in a clinical trial with an investigational drug within 30 days prior to first study drug administration.
- •·History of alcohol and/or other substance abuse or addiction within the last year.
- •·Positive screening for drugs of abuse at screening and at Day -1.
- •·Donation of >500 mL of blood within the 2 months preceding first study drug administration.
- •·Positive virology screen for HIV or Hepatitis B or C.
- •·History of significant drug allergy or drug hypersensitivity
- •·Subject not willing to comply to a diabetic diet
- •Present Condition:
- •·Clinically relevant deviations of any finding during the pre-study examination
- •- vital signs
- •- physical examination
- •- laboratory tests
- •·Severe, controlled/uncontrolled hypertension (SBP >170 mmHg and/or DBP > 100 mmHg) in the supine position
- •·Treated hypertensive patients who are not on a stable antihypertensive medication for at least 4 weeks.
- •·Impaired renal function: creatinine =150 µM.
- •·Impaired hepatic function (ALT, AST or alkaline phosphatase =3 times upper normal limit).
- •·Female subjects of child bearing potential (only female subjects who are postmenopausal [12 month of spontaneous amenorrhea at screening] or surgically sterile [bilateral oophorectomy with or without hysterectomy] or hysterectomy without oophorectomy may be enrolled)
- •·Refusal or inability to give written informed consent
- •·Inability to participate in the entire trial period
研究者
相似试验
已完成
3 期
A double-blind, placebo-controlled, dose-escalation, parallel-group study to evaluate the efficacy and safety of E2007 (perampanel) given as adjunctive therapy in subjects with refractory partial seizures.epilepsyNL-OMON35288Eisai50
进行中（未招募）
1 期
A double-blind, placebo-controlled study with increasing doses of chemically modified tree pollen drops in patients suffering from allergicinflammation of the conjunctiva and rhinitis which are caused by tree pollen allergens.Treatment of tree pollen-induced allergic rhinoconjunctivitisMedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853EUCTR2017-003063-34-DEofarma S.p.A.48
已完成
不适用
A double-blind, placebo-controlled, dose escalation study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of KCP506 in healthy subjectsChronic painchronic painNL-OMON55203Kineta Chronic Pain, LLC108
进行中（未招募）
不适用
A Double-blind, Placebo-controlled, Dose-escalation, Parallel Group Study of E2007 given as Adjunctive Therapy in Patients with Refractory Partial SeizuresE2007 is given as adjunctive therapy in patients with refractory partial seizuresMedDRA version: 9.1Level: LLTClassification code 10061334Term: Partial seizuresEUCTR2005-004199-18-LTEisai Limited144
进行中（未招募）
不适用
A Double-blind, Placebo-controlled, Dose-escalation, Parallel Group Study of E2007 given as Adjunctive Therapy in Patients with Refractory Partial SeizuresE2007 is given as adjunctive therapy in patients with refractory partial seizuresEUCTR2005-004199-18-SEEisai Limited144